Aberrant SRC expression is detected in most GCs and is also associated with cancer progression and poor prognosis [6,7,8,9], providing a clinical rationale for the use of SFK inhibitors as effective targeted therapy for the treatment of GC. The gene discussed is SRC; the disease is cancer.